EA Pharma Launches Late-stage Trial of Newron Pharmaceuticals' Schizophrenia Drug in Japan

MT Newswires · 4d ago
01:58 AM EST, 01/07/2026 (MT Newswires) -- Swiss-listed biopharmaceutical company Newron Pharmaceuticals (NWRN.SW) said Wednesday that its partner EA Pharma Co. initiated a phase 3 trial of its Schizophrenia treatment EA8001, or Evenamide, in Japan. The multicenter, randomized, double-blind, and placebo-controlled study aims to assess the efficacy, safety, and tolerability of Evenamide as an add-on treatment in patients with treatment-resistant schizophrenia.